SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.580-3.0%Oct 28 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JJINV who wrote (1210)10/26/2025 3:11:39 PM
From: waitwatchwander3 Recommendations

Recommended By
Fitzhughlaw
JJINV
Stanley Lake 92

  Read Replies (2) of 1216
 
He makes some good points as to the study. His critique as to credibility of survivability is based upon similar reasoning.

PSS has been dealing with later stage cancer patients for much of his medical career. I'm sure he does have a good anecdotal take on the value of Anktiva.

Concerns About Study Design

- No control group or comparator arm.
- Lymphocyte count thresholds were defined retrospectively, introducing bias.
- The frequency and consistency of lymphocyte measurements were unclear.

Feuerstein suggests these flaws undermine the credibility of the survival benefit claims.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News